Baseline SGLT2 inhibitor therapy was associated with a 70% reduction in all-cause mortality (HR 0.300) in patients with cancer and type 2 diabetes treated with immune checkpoint inhibitors.
Cohort (n=119)
No
Does SGLT2i therapy reduce all-cause mortality and cardiotoxicity in patients with cancer and type 2 diabetes treated with immune checkpoint inhibitors?
In patients with cancer and type 2 diabetes treated with immune checkpoint inhibitors, baseline SGLT2i therapy is associated with significantly reduced all-cause mortality.
Hazard Ratio: 0.3 (95% CI 0.104–0.865)
Absolute Event Rate: 21% vs 59%
p-value: p=0.026
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective antidiabetic therapies associated with reduced all-cause mortality and cardiovascular (CV) outcomes. OBJECTIVE: To evaluate the prognostic value of SGLT2i on all-cause mortality and cardiotoxicity among patients treated with ICIs. METHODS: We performed a retrospective analysis of patients diagnosed with cancer and type 2 DM (DM2) and treated with ICIs at our center. Patients were divided into two groups according to baseline treatment with or without SGLT2i. The primary endpoint was all-cause mortality and the secondary endpoint was MACE, including myocarditis, acute coronary syndrome, heart failure, and arrhythmia. RESULTS: The cohort included 119 patients, with 24 (20%) patients assigned to the SGLT2i group. Both groups exhibited a comparable prevalence of cardiac risk factors, although the SGLT2i group displayed a higher incidence of ischemic heart disease. Over a median follow-up of 28 months, 61 (51%) patients died, with a significantly lower all-cause mortality rate in the SGLT2i group (21% vs. 59%, p = 0.002). While there were no significant differences in MACE, we observed zero cases of myocarditis and atrial fibrillation in the SGLT2i, compared to 2 and 6 cases in the non-SGLT2i group. CONCLUSIONS: SGLT2i therapy was associated with a lower all-cause mortality rate in patients diagnosed with cancer and DM2 and treated with ICIs. Further studies are needed to understand the mechanism and evaluate its benefit on cardiotoxicity.
Perelman et al. (Thu,) conducted a cohort in Cancer and type 2 diabetes mellitus (n=119). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. No SGLT2i was evaluated on All-cause mortality (HR 0.300, 95% CI 0.104-0.865, p=0.026). Baseline SGLT2 inhibitor therapy was associated with a 70% reduction in all-cause mortality (HR 0.300) in patients with cancer and type 2 diabetes treated with immune checkpoint inhibitors.